By tracking the changes in prostate cancer cells over time, researchers at the Johns Hopkins Kimmel Cancer Center have found that activation of the MYC gene — a well-known cancer-causing gene — sets off a cascade of events that leads to both initiation and progression of the disease.
September is National Sickle Cell Awareness Month. Experts from Johns Hopkins Medicine who specialize in sickle cell disease are available to discuss health equity issues related to sickle cell disease.
Nadia Hansel, M.D., a pulmonary and critical care physician and expert in the environmental determinants of obstructive lung diseases, has been named director of the Department of Medicine at the Johns Hopkins University School of Medicine and physician-in-chief of The Johns Hopkins Hospital. Hansel is the William Osler Professor of Medicine. She is the first woman to lead the storied Department of Medicine in its 131-year history.
Brenda Banwell, M.D., has been named pediatrician-in-chief and co-director of Johns Hopkins Children’s Center. She also serves as director of the Department of Pediatrics at the Johns Hopkins University School of Medicine. Banwell began in the position on Sept. 1, 2024.
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
Age-related changes in the fibroblasts, cells that create the skin’s structure, contribute to the development of aggressive, treatment-resistant melanoma in males, according to research in mice by the Johns Hopkins Kimmel Cancer Center.
In a study using human breast cancer cells, scientists say they have potentially identified immune system white blood cells that appear to be the closest neighbors of breast cancer cells that are likely to spread.
Using a new workflow that integrates spatial transcriptomics and machine learning for imaging analysis and integration with single-cell datasets, researchers at the Johns Hopkins Kimmel Cancer Center have identified novel molecular and cellular markers in the development of one of the most aggressive, deadly pancreatic cancers: pancreatic ductal adenocarcinoma (PDAC).
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.
A novel test developed by Johns Hopkins Kimmel Cancer Center investigators could give gastroenterologists insight into which patients with Barrett’s esophagus — a premalignant condition in which parts of the esophagus become damaged by chronic acid reflux — are likely to progress to esophageal cancer or an abnormal collection of cells called high-grade dysplasia.
In what they labeled a “surprising” finding, Johns Hopkins Medicine researchers studying bacteria from freshwater lakes and soil say they have determined a protein’s essential role in maintaining the germ’s shape.
In a preliminary study with a small number of humans, rabbits and mice, researchers at Johns Hopkins Children’s Center say they have developed four new regimens that have the potential to treat and save the lives of people with multidrug-resistant (MDR) tuberculous (TB) meningitis.
A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic discovery made at the Johns Hopkins Kimmel Cancer Center.
Working with human stem cells that form a kind of “mini intestine-in-a-dish,” Johns Hopkins Medicine scientists say they have found several molecular mechanisms for COVID-19-related diarrhea, suggesting potential ways to control it.
A new small study led by Johns Hopkins Medicine researchers and published July 25th in the journal Nature Cardiovascular Research has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).
In a rigorous medical records study covering tens of thousands of patients, Johns Hopkins Medicine researchers conclude that some patients with preoperative anemia have better outcomes if they get iron infusions before surgery rather than standard red blood cell transfusions.
With renewed funding of up to $98.8 million for seven years, Johns Hopkins Medicine scientists will continue to be a worldwide resource for discovering the genes and their variations that contribute to human disease.
Johns Hopkins Medicine researchers have published new research that reports on a potential alternative and less-invasive approach to measure intracranial pressure (ICP) in patients.
What does science tell us about being an Olympic athlete? The answer depends on which Johns Hopkins Medicine scientist you ask.For interviews with the experts on these topics, contact Alexandria Carolan ([email protected]) or Vanessa Wasta ([email protected]).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right